The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters

被引:41
|
作者
Winkler, Ulrich H. [1 ]
Sudik, Roland [2 ]
机构
[1] Clin Wetzlar Braunfels, Dept Obstet & Gynaecol, D-33578 Wetzlar, Germany
[2] Klinikum Neubrandenhurg, Dept Obstet & Gynecol, D-17036 Neubrandenburg, Germany
关键词
Chlormadinone acetate; Ethinyl estradiol; Desogestrel; Oral contraceptive; VENOUS THROMBOEMBOLIC DISEASE; RISK; LIPOPROTEINS; MORTALITY; ETHINYLESTRADIOL; 3RD-GENERATION; BELARA(R); ESTROGEN; ACNE;
D O I
10.1016/j.contraception.2008.08.011
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: This study was conducted to compare the effects of two monophasic oral contraceptives (OCs) containing ethinyl estradiol (EE) 30 mcg+either chlormadinone acetate (CMA) 2 mg (Belara (R)) or 0.15 mg desogestrel (Marvelon (R)) on lipid, hormone and other relevant metabolic parameters. Study design: Markers of lipid and carbohydrate metabolism, and reproductive hormone levels, were measured in 45 Subjects randomly assigned to 6 months of treatment with one of the two OCs. The cortisol response to adrenocorticotrophic hormone (ACTH) stimulation was also evaluated. Results: In both treatment groups, triglycerides, high-density lipoprotein cholesterol (HDL-C), apolipoprotein (Apo) Al and Apo All levels increased; low-density lipoprotein cholesterol (LDL-C) and the LDL-C/HDL-C ratio decreased; and total cholesterol and lipoprotein(a) were unchanged during treatment. Effects on HDL-C, Apo Al, LDL-C and the LDL-C/HDL-C ratio were more evident in the EE 30 mcg+CMA 2 mg group. Follicle-stimulating hormone, luteinizing hormone and androgen levels decreased and sex hormone-binding globulin levels increased in both groups. Both OCs increased basal cortisol levels and cortisol response to ACTH. Oral contraceptive did not have a clinically significant impact on carbohydrate metabolism. Conclusions: Both low-dose monophasic OCs had comparable effects on lipid, hormone and metabolic parameters during six cycles of treatment in healthy female subjects. There was some evidence of a beneficial effect on atherogenic cardiovascular risk markers, which was slightly more pronounced with EE 30 mcg+CMA 2 mg. (C) 2009 Published by Elsevier Inc.
引用
收藏
页码:15 / 23
页数:9
相关论文
共 27 条
  • [11] An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables
    Winkler, Ulrich H.
    Roehm, Petra
    Hoeschen, Kornelia
    CONTRACEPTION, 2010, 81 (05) : 391 - 400
  • [12] Suppression of ovarian function by a combined oral contraceptive containing 0.02 mg ethinyl estradiol and 2 mg chlormadinone acetate given in a 24/4-day intake regimen over three cycles
    Spona, Juergen
    Binder, Natascha
    Hoeschen, Kornelia
    Feichtinger, Wilfried
    FERTILITY AND STERILITY, 2010, 94 (04) : 1195 - 1201
  • [13] Oral contraceptives that contain ethinyl estradiol (0.035 mg) and cyproterone acetate (2 mg) inhibit leukocyte transmigration through endothelial cell monolayers
    Hofbauer, R
    Frass, M
    Gmeiner, B
    Salfinger, H
    Salzer, H
    Kos, T
    Wagner, O
    Kapiotis, S
    Kaye, AD
    FERTILITY AND STERILITY, 1999, 72 (04) : 652 - 656
  • [14] Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters
    Wiegratz, I
    Jung-Hoffmann, C
    Gross, W
    Kuhl, H
    CONTRACEPTION, 1998, 58 (02) : 83 - 91
  • [15] Evaluation of efficacy, safety and effects on symptoms of androgenization of a generic oral contraceptive containing chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg
    Hadji, Peyman
    Biskup, Jutta
    Boekhoff, Jelena
    Ziller, May
    Bonn, Michael
    Rovati, Lucio
    CONTRACEPTION, 2012, 86 (04) : 359 - 365
  • [16] Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 mu g ethinyl estradiol and 2.00 mg dienogest on the hemostatic system
    Spona, J
    Feichtinger, W
    Kindermann, C
    Schneider, B
    Mellinger, U
    Walter, F
    Moore, C
    Graser, T
    CONTRACEPTION, 1997, 56 (02) : 67 - 75
  • [17] Fertility after discontinuation of treatment with an oral contraceptive containing 30 μg of ethinyl estradiol and 2 mg of dienogest
    Wiegratz, Inka
    Mittmann, Katrin
    Dietrich, Horst
    Zimmermann, Thomas
    Kuhl, Herbert
    FERTILITY AND STERILITY, 2006, 85 (06) : 1812 - 1819
  • [18] Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen over six cycles
    Rabe, Thomas
    Hartschuh, Elena
    Wahlstrom, Torsten
    Hoeschen, Kornelia
    Koenig, Simone
    CONTRACEPTION, 2010, 82 (04) : 358 - 365
  • [19] Effects of two oral contraceptives, containing 30 or 20 μg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women
    Ferreira, ACP
    Montes, MBA
    Franceschini, SA
    Toloi, MRT
    INTERNATIONAL JOURNAL OF FERTILITY AND WOMENS MEDICINE, 2001, 46 (05): : 265 - 270
  • [20] Effects of two estroprogestins containing ethynilestradiol 30 μg and drospirenone 3 mg and ethynilestradiol 30 μg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations
    Lello, Stefano
    Primavera, Grazia
    Colonna, Laura
    Vittori, Giorgio
    Guardianelli, Francesca
    Sorge, Roberto
    Raskovic, Desanka
    GYNECOLOGICAL ENDOCRINOLOGY, 2008, 24 (12) : 718 - 723